1 Study Coverage 1.1 Hemoglobinopathy Drugs Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Introduction 1.2 Global Hemoglobinopathy Drugs Outlook 2017 VS 2022 VS 2028 1.2.1 Global Hemoglobinopathy Drugs Market Size for the Year 2017-2028 1.2.2 Global Hemoglobinopathy Drugs Market Size for the Year 2017-2028 1.3 Hemoglobinopathy Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Hemoglobinopathy Drugs in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Hemoglobinopathy Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Hemoglobinopathy Drugs Market Dynamics 1.4.1 Hemoglobinopathy Drugs Industry Trends 1.4.2 Hemoglobinopathy Drugs Market Drivers 1.4.3 Hemoglobinopathy Drugs Market Challenges 1.4.4 Hemoglobinopathy Drugs Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Hemoglobinopathy Drugs by Type 2.1 Hemoglobinopathy Drugs Market Segment by Type 2.1.1 Hydroxyurea 2.1.2 Glutamine 2.1.3 Zynteglo 2.1.4 Other 2.2 Global Hemoglobinopathy Drugs Market Size by Type (2017, 2022 & 2028) 2.3 Global Hemoglobinopathy Drugs Market Size by Type (2017-2028) 2.4 United States Hemoglobinopathy Drugs Market Size by Type (2017, 2022 & 2028) 2.5 United States Hemoglobinopathy Drugs Market Size by Type (2017-2028) 3 Hemoglobinopathy Drugs by Application 3.1 Hemoglobinopathy Drugs Market Segment by Application 3.1.1 Sickle Cell Diseases 3.1.2 Thalassemia 3.2 Global Hemoglobinopathy Drugs Market Size by Application (2017, 2022 & 2028) 3.3 Global Hemoglobinopathy Drugs Market Size by Application (2017-2028) 3.4 United States Hemoglobinopathy Drugs Market Size by Application (2017, 2022 & 2028) 3.5 United States Hemoglobinopathy Drugs Market Size by Application (2017-2028) 4 Global Hemoglobinopathy Drugs Competitor Landscape by Company 4.1 Global Hemoglobinopathy Drugs Market Size by Company 4.1.1 Top Global Hemoglobinopathy Drugs Companies Ranked by Revenue (2021) 4.1.2 Global Hemoglobinopathy Drugs Revenue by Player (2017-2022) 4.2 Global Hemoglobinopathy Drugs Concentration Ratio (CR) 4.2.1 Hemoglobinopathy Drugs Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Hemoglobinopathy Drugs in 2021 4.2.3 Global Hemoglobinopathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Hemoglobinopathy Drugs Headquarters, Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Type 4.3.1 Global Hemoglobinopathy Drugs Headquarters and Area Served 4.3.2 Global Hemoglobinopathy Drugs Companies Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Hemoglobinopathy Drugs Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Hemoglobinopathy Drugs Market Size by Company 4.5.1 Top Hemoglobinopathy Drugs Players in United States, Ranked by Revenue (2021) 4.5.2 United States Hemoglobinopathy Drugs Revenue by Players (2020, 2021 & 2022) 5 Global Hemoglobinopathy Drugs Market Size by Region 5.1 Global Hemoglobinopathy Drugs Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Hemoglobinopathy Drugs Market Size by Region (2017-2028) 5.2.1 Global Hemoglobinopathy Drugs Market Size by Region: 2017-2022 5.2.2 Global Hemoglobinopathy Drugs Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Hemoglobinopathy Drugs Market Size YoY Growth 2017-2028 6.1.2 North America Hemoglobinopathy Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Hemoglobinopathy Drugs Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Hemoglobinopathy Drugs Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Hemoglobinopathy Drugs Market Size YoY Growth 2017-2028 6.3.2 Europe Hemoglobinopathy Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Hemoglobinopathy Drugs Market Size YoY Growth 2017-2028 6.4.2 Latin America Hemoglobinopathy Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Hemoglobinopathy Drugs Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Hemoglobinopathy Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Novartis 7.1.1 Novartis Company Details 7.1.2 Novartis Business Overview 7.1.3 Novartis Hemoglobinopathy Drugs Introduction 7.1.4 Novartis Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.1.5 Novartis Recent Development 7.2 AstraZeneca 7.2.1 AstraZeneca Company Details 7.2.2 AstraZeneca Business Overview 7.2.3 AstraZeneca Hemoglobinopathy Drugs Introduction 7.2.4 AstraZeneca Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.2.5 AstraZeneca Recent Development 7.3 Bluebird 7.3.1 Bluebird Company Details 7.3.2 Bluebird Business Overview 7.3.3 Bluebird Hemoglobinopathy Drugs Introduction 7.3.4 Bluebird Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.3.5 Bluebird Recent Development 7.4 Bristol-Myers Squibb 7.4.1 Bristol-Myers Squibb Company Details 7.4.2 Bristol-Myers Squibb Business Overview 7.4.3 Bristol-Myers Squibb Hemoglobinopathy Drugs Introduction 7.4.4 Bristol-Myers Squibb Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.4.5 Bristol-Myers Squibb Recent Development 7.5 Emmaus Medical 7.5.1 Emmaus Medical Company Details 7.5.2 Emmaus Medical Business Overview 7.5.3 Emmaus Medical Hemoglobinopathy Drugs Introduction 7.5.4 Emmaus Medical Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.5.5 Emmaus Medical Recent Development 7.6 Acceleron Pharma 7.6.1 Acceleron Pharma Company Details 7.6.2 Acceleron Pharma Business Overview 7.6.3 Acceleron Pharma Hemoglobinopathy Drugs Introduction 7.6.4 Acceleron Pharma Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.6.5 Acceleron Pharma Recent Development 7.7 HemaQuest Pharmaceuticals 7.7.1 HemaQuest Pharmaceuticals Company Details 7.7.2 HemaQuest Pharmaceuticals Business Overview 7.7.3 HemaQuest Pharmaceuticals Hemoglobinopathy Drugs Introduction 7.7.4 HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.7.5 HemaQuest Pharmaceuticals Recent Development 7.8 Eli Lilly and Company 7.8.1 Eli Lilly and Company Company Details 7.8.2 Eli Lilly and Company Business Overview 7.8.3 Eli Lilly and Company Hemoglobinopathy Drugs Introduction 7.8.4 Eli Lilly and Company Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.8.5 Eli Lilly and Company Recent Development 7.9 Celgene 7.9.1 Celgene Company Details 7.9.2 Celgene Business Overview 7.9.3 Celgene Hemoglobinopathy Drugs Introduction 7.9.4 Celgene Revenue in Hemoglobinopathy Drugs Business (2017-2022) 7.9.5 Celgene Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Hemoglobinopathy Drugs Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Hemoglobinopathy Drugs Market Trends Table 3. Hemoglobinopathy Drugs Market Drivers Table 4. Hemoglobinopathy Drugs Market Challenges Table 5. Hemoglobinopathy Drugs Market Restraints Table 6. Global Hemoglobinopathy Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Hemoglobinopathy Drugs Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Hemoglobinopathy Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Hemoglobinopathy Drugs Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Hemoglobinopathy Drugs Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Hemoglobinopathy Drugs Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Hemoglobinopathy Drugs Revenue Share by Player, 2017-2022 Table 13. Global Hemoglobinopathy Drugs Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Hemoglobinopathy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathy Drugs as of 2021) Table 15. Top Players of Hemoglobinopathy Drugs in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Hemoglobinopathy Drugs Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Hemoglobinopathy Drugs Players in United States Market, Ranking by Revenue (2021) Table 20. United States Hemoglobinopathy Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Hemoglobinopathy Drugs Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Hemoglobinopathy Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Hemoglobinopathy Drugs Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Hemoglobinopathy Drugs Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Hemoglobinopathy Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Hemoglobinopathy Drugs Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Hemoglobinopathy Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Hemoglobinopathy Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Hemoglobinopathy Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Novartis Company Details Table 31. Novartis Business Overview Table 32. Novartis Hemoglobinopathy Drugs Product Table 33. Novartis Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 34. Novartis Recent Development Table 35. AstraZeneca Company Details Table 36. AstraZeneca Business Overview Table 37. AstraZeneca Hemoglobinopathy Drugs Product Table 38. AstraZeneca Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 39. AstraZeneca Recent Development Table 40. Bluebird Company Details Table 41. Bluebird Business Overview Table 42. Bluebird Hemoglobinopathy Drugs Product Table 43. Bluebird Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 44. Bluebird Recent Development Table 45. Bristol-Myers Squibb Company Details Table 46. Bristol-Myers Squibb Business Overview Table 47. Bristol-Myers Squibb Hemoglobinopathy Drugs Product Table 48. Bristol-Myers Squibb Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 49. Bristol-Myers Squibb Recent Development Table 50. Emmaus Medical Company Details Table 51. Emmaus Medical Business Overview Table 52. Emmaus Medical Hemoglobinopathy Drugs Product Table 53. Emmaus Medical Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 54. Emmaus Medical Recent Development Table 55. Acceleron Pharma Company Details Table 56. Acceleron Pharma Business Overview Table 57. Acceleron Pharma Hemoglobinopathy Drugs Product Table 58. Acceleron Pharma Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 59. Acceleron Pharma Recent Development Table 60. HemaQuest Pharmaceuticals Company Details Table 61. HemaQuest Pharmaceuticals Business Overview Table 62. HemaQuest Pharmaceuticals Hemoglobinopathy Drugs Product Table 63. HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 64. HemaQuest Pharmaceuticals Recent Development Table 65. Eli Lilly and Company Company Details Table 66. Eli Lilly and Company Business Overview Table 67. Eli Lilly and Company Hemoglobinopathy Drugs Product Table 68. Eli Lilly and Company Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 69. Eli Lilly and Company Recent Development Table 70. Celgene Company Details Table 71. Celgene Business Overview Table 72. Celgene Hemoglobinopathy Drugs Product Table 73. Celgene Revenue in Hemoglobinopathy Drugs Business (2017-2022) & (US$ Million) Table 74. Celgene Recent Development Table 75. Research Programs/Design for This Report Table 76. Key Data Information from Secondary Sources Table 77. Key Data Information from Primary Sources List of Figures Figure 1. Hemoglobinopathy Drugs Product Picture Figure 2. Global Hemoglobinopathy Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Hemoglobinopathy Drugs Market Size 2017-2028 (US$ Million) Figure 4. United States Hemoglobinopathy Drugs Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Hemoglobinopathy Drugs Market Size 2017-2028 (US$ Million) Figure 6. United States Hemoglobinopathy Drugs Market Share in Global 2017-2028 Figure 7. Hemoglobinopathy Drugs Report Years Considered Figure 8. Product Picture of Hydroxyurea Figure 9. Product Picture of Glutamine Figure 10. Product Picture of Zynteglo Figure 11. Product Picture of Other Figure 12. Global Hemoglobinopathy Drugs Market Share by Type in 2022 & 2028 Figure 13. Global Hemoglobinopathy Drugs Market Size by Type (2017-2028) & (US$ Million) Figure 14. Global Hemoglobinopathy Drugs Market Share by Type (2017-2028) Figure 15. United States Hemoglobinopathy Drugs Market Share by Type in 2022 & 2028 Figure 16. United States Hemoglobinopathy Drugs Market Size by Type (2017-2028) & (US$ Million) Figure 17. United States Hemoglobinopathy Drugs Market Share by Type (2017-2028) Figure 18. Product Picture of Sickle Cell Diseases Figure 19. Product Picture of Thalassemia Figure 20. Global Hemoglobinopathy Drugs Market Share by Application in 2022 & 2028 Figure 21. Global Hemoglobinopathy Drugs Market Size by Application (2017-2028) & (US$ Million) Figure 22. Global Hemoglobinopathy Drugs Market Share by Application (2017-2028) Figure 23. United States Hemoglobinopathy Drugs Market Share by Application in 2022 & 2028 Figure 24. United States Hemoglobinopathy Drugs Market Size by Application (2017-2028) & (US$ Million) Figure 25. United States Hemoglobinopathy Drugs Market Share by Application (2017-2028) Figure 26. North America Hemoglobinopathy Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 27. U.S. Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 28. Canada Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Europe Hemoglobinopathy Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 30. Germany Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. France Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. U.K. Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. Italy Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Russia Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Asia-Pacific Hemoglobinopathy Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 36. China Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Japan Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. South Korea Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. India Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Australia Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Taiwan Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Indonesia Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Thailand Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Malaysia Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Philippines Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Latin America Hemoglobinopathy Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 47. Mexico Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Brazil Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Argentina Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Middle East & Africa Hemoglobinopathy Drugs Market Size Growth Rate 2017-2028 (US$ Million) Figure 51. Turkey Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. Saudi Arabia Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. U.A.E Hemoglobinopathy Drugs Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. Novartis Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 55. AstraZeneca Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 56. Bluebird Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 58. Emmaus Medical Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 59. Acceleron Pharma Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 60. HemaQuest Pharmaceuticals Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 61. Eli Lilly and Company Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 62. Celgene Revenue Growth Rate in Hemoglobinopathy Drugs Business (2017-2022) Figure 63. Bottom-up and Top-down Approaches for This Report Figure 64. Data Triangulation Figure 65. Key Executives Interviewed

Novartis AstraZeneca Bluebird Bristol-Myers Squibb Emmaus Medical Acceleron Pharma HemaQuest Pharmaceuticals Eli Lilly and Company Celgene